Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Sabuwar Maganin Layin Farko don Ciwon Ciwon Ciki/GEJ Ciwon daji

Written by edita

Trishula Therapeutics, Inc.. gastroesophageal junction ciwon daji. An gabatar da sakamakon binciken a cikin gabatarwar baka a Ƙungiyar Amirka don Binciken Ciwon daji (AACR) Taron Shekara-shekara a New Orleans. Bayanan da aka gabatar ya nuna cewa TTX-1 hade da jiyya an yi haƙuri sosai kuma ya nuna alamun ƙarfafawa na aikin ƙwayar cuta.

"Hanyoyin amsawa ciki har da marasa lafiya tare da ƙananan ciwace-ciwacen ƙwayar cuta na PD-L1 da aka gani a cikin wannan bincike na farko yana ƙarfafawa sosai da kuma tallafawa yiwuwar TTX-030 don tasiri ga ma'auni na kulawa ga marasa lafiya da ciwon ciki da kuma gastroesophageal ciwon daji," in ji Zev Wainberg, MD. Farfesa na Magunguna a UCLA kuma darektan UCLA GI Oncology Program. "Muna sa ran samun cikakken sakamakon wannan gwaji da kuma ci gaban wannan kyakkyawar hanyar magani."

An gabatar da ingantaccen sakamako na farko da aminci kamar yadda aka yanke bayanan wucin gadi na Maris 1, 2022. An yi rajistar marasa lafiya 44 duka. Marasa lafiya ashirin da shida (26) har yanzu suna kan jiyya na nazarin, kuma tsawon lokaci akan binciken shine kwanaki 214 (kewayon 8-464 + kwanaki). Daga cikin marasa lafiya na 40 masu inganci, marasa lafiya 21 (marasa lafiya 25 ciki har da waɗanda ba a tabbatar da su ba) sun sami mafi kyawun amsawar juzu'i na juzu'i ko mafi kyau ciki har da 4 CRs: ORR = 52.5% (62,5% ciki har da wanda ba a tabbatar da shi ba), da ƙimar kula da cututtuka = ​​92.5%. Talatin da bakwai (37) na inganci-ƙimar marasa lafiya sun san PD-L1 Combined Positive Score (CPS); Yawan amsawa a cikin marasa lafiya tare da CPS ≥1 sun kasance 65% (77% ciki har da waɗanda ba a tabbatar da su ba).

Ashirin da bakwai na marasa lafiya na 44 (61%) sun sami akalla wani abu mara kyau (AE) na kowane matsayi da aka yi la'akari da TTX-030 (kimanin mai bincike), ciki har da marasa lafiya 9 (20.5%) tare da Grade 3 / 4 AEs. Abubuwan da ba su da kyau sun yi daidai da waɗanda aka gani tare da daidaitattun kulawa (chemotherapy da anti-PD-1).

Anil Singhal, Babban Jami'in Gudanarwa ya ce "Bayanan mu da aka ba da haske a AACR suna wakiltar alamun farko na asibiti na rigakafin CD39 a cikin marasa lafiya da ciwon daji na ciki kuma suna tallafawa rawar TTX-030 don juyar da maganin rigakafi na adenosine," in ji Anil Singhal, Babban Jami'in Gudanarwa. "Muna sa ran ci gaba da ci gaban wannan binciken na asibiti na TTX-030, wanda muka yi imanin yana da yuwuwar inganta yanayin jiyya ga masu cutar kansa."

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...